SCHEMBL19700758

SCHEMBL19700758

NCCCCCCOC1OC(CO)C(O)C(O)C1NC(=O)C(F)(F)F

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.58
▸ LGALS8 O00214 2/20 0.48
▸ LGALS3 P17931 2/20 0.48
▸ LGALS4 P56470 2/20 0.48
▸ CA1 P00915 4/20 0.45
▸ CA2 P00918 4/20 0.45
▸ CA9 Q16790 4/20 0.45
▸ IFNG P01579 1/20 0.40
▸ FGF1 P05230 1/20 0.40
▸ FGF2 P09038 1/20 0.40
▸ BMP2 P12643 1/20 0.40
▸ VEGFA P15692 1/20 0.40
▸ SFRP1 Q8N474 1/20 0.40
▸ B4GALT1 P15291 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ IGF2R P11717 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18349755 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL16392946 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL16392943 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL16393098 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL16393103 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL18349900 0.86 MAPK1 (0.56) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL19700761 0.85 MAPK1 (0.60) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL25480938 0.85 MAPK1 (0.80) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL10002199 0.85 MAPK1 (0.80) MAPK1LGALS8LGALS3LGALS4CA1
SCHEMBL17932962 0.85 MAPK1 (0.80) MAPK1LGALS8LGALS3LGALS4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355727-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE IONIS PHARMACEUTICALS, INC. (US) 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355727-A1 CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE GNE, GALNT1, GALNT6 MAPK1 3820/4885LGALS8 31/4885LGALS3 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback